Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Fibromyalgia patients taking GLP-1s have lower rates of opioid use, pain, fatigue, and malaise in a real-world patient data ...

There’s no doubt that GLP-1 drugs like Ozempic have been revolutionary — although the benefits do sometimes come with some ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.

GLP-1 medications have become game changers for people trying to lose weight, but bariatric surgery is still superior when it comes to total and lasting weight loss, a new study has found.

MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron.

Thirty patients with prediabetes ended up developing type 2 diabetes, including 11 who discontinued GLP-1 treatment early, 11 who discontinued late, and 8 who never discontinued (P < .001).

Janelle Rohner is microdosing a GLP-1,” Rohner wrote in a YouTube description for a video at the time. “I’ve quietly been working on my mental health, trying to find peace in the chaos.

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing the… ...

All participants had previously been treated with a GLP-1 therapy for durations ranging from approximately 5 months to 3 years, with a median total body weight (TBW) loss of 20.9% while on therapy.

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination ...